Pioneering the Next Generation of Allogeneic Cell Therapies

Overcoming Cost and Manufacturing Bottlenecks to Democratize Access

At Luminary Therapeutics, we are dismantling the economic and manufacturing barriers of traditional CAR-T. By shifting from slow, patient-specific (autologous) processes to an optimized, off-the-shelf allogeneic γδ platform, we are transforming patient access.

Hundreds of Doses, One Donor: We replace bespoke manufacturing with a platform that yields hundreds of doses from a single healthy donor.
Immediate Access: Cryopreserved and ready for on-demand clinical use, bypassing life-threatening production delays.
Global Affordability: Built from the ground up to drastically reduce costs and make cell therapy scalable worldwide.

Our Pipeline Focus: Autoimmune Disease & Oncology

Hematologic Malignancies

By simultaneously targeting three distinct receptors across the B-cell lineage, our BAFF-L CAR achieves a profound depletion of pathological B-cells, overcoming resistance seen in traditional single-target therapies.

Targeted Autoimmune Reset

We leverage our proprietary BAFF-L CAR-T therapy for precise immune ablation, aiming to deliver durable, drug-free remission for patients with severe autoimmune disorders.

Solid Tumor Breakthroughs

Through innovative dual-targeting architectures, we engineer therapies designed to dismantle the immunosuppressive tumor microenvironment, combat antigen escape, and break the barriers that have historically limited cell therapy in solid oncology.

Program	Status	Cell Type	Product	Discovery / Pre-Clinical	Patients Treated	Clinical Trial
BAFF-L CAR	Active / Enrolling	αβ T cell	LMY-920	Non-Hodgkin Lymphoma (NHL)	7	Cleveland Clinic NCT05312801
				Multiple Myeloma (MM)	3	University Hospitals (UH) NCT05546723
				Chronic Lymphocytic Leukemia (CLL)	3	Cleveland Clinic NCT07679919
				Systemic Lupus Erythematosus (SLE)	3	Nationwide Children's Hospital NCT06340750
		γδ T cell	LMY-922	Hematologic Cancers Basket Trial	Soon	Cleveland Clinic NCT07679919
		γδ T cell	LMY-922	Autoimmune Basket Trial	Soon	Boston Children's Hospital NCT07729995

Dual-Targeting Split CAR Technology	Upcoming	γδ T cell	LMY-232	Renal Carcinoma / Esophageal
	Upcoming	γδ T cell	LMY-252	Lung / Colorectal
	In development	γδ T cell	LMY-272	Osteosarcoma

Autoimmune trials are italicized

PIPELINE

Pioneering the Next Generation of Allogeneic Cell Therapies

Our Pipeline Focus: Autoimmune Disease & Oncology

Hematologic Malignancies

Targeted Autoimmune Reset

Solid Tumor Breakthroughs